Non-small cell lung cancer metastatic Trials in Paris, France
Conditions / Non-small cell lung cancer metastatic / Paris, France
Non-small cell lung cancer metastatic has been the subject of sustained clinical investigation across multiple research sites.
20 total trials for this combination
Showing top 10 of 20 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07144280 | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | RECRUITING | — |
| NCT04154956 | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07144280 | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | RECRUITING | — |
| NCT07144280 | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | RECRUITING | — |
| NCT03774732 | PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01935154 | Efficacy Study of Vx001 Vaccine in NSCLC Patients | COMPLETED | PHASE2 |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC | TERMINATED | PHASE3 |
| NCT07563205 | Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer | RECRUITING | — |
| NCT04619004 | HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |